A1CLJ

17-(cyclopropylmethyl)-3,14-dihydroxy-5alpha-4,5-epoxymorphinan-6-one

Created:	2025-08-01
Last modified:	2026-03-04

Find Related PDB Entry
1 entries where A1CLJ is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	48
Chiral Atom Count	4
Bond Count	53
Aromatic Bond Count	6

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	17-(cyclopropylmethyl)-3,14-dihydroxy-5alpha-4,5-epoxymorphinan-6-one
Systematic Name (OpenEye OEToolkits)	(4~{R},4~{a}~{S},7~{a}~{R},12~{b}~{S})-3-(cyclopropylmethyl)-4~{a},9-bis(oxidanyl)-2,4,5,6,7~{a},13-hexahydro-1~{H}-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Formula	C₂₀ H₂₃ N O₄
Molecular Weight	341.401
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	14.52	O=C1CCC2(O)C3Cc4ccc(O)c5OC1C2(CCN3CC1CC1)c54
SMILES	CACTVS	3.385	Oc1ccc2C[CH]3N(CC[C]45[CH](Oc1c24)C(=O)CC[C]35O)CC6CC6
SMILES	OpenEye OEToolkits	3.1.0.0	c1cc(c2c3c1CC4C5(C3(CCN4CC6CC6)C(O2)C(=O)CC5)O)O
Canonical SMILES	CACTVS	3.385	Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC6CC6
Canonical SMILES	OpenEye OEToolkits	3.1.0.0	c1cc(c2c3c1C[C@@H]4[C@]5([C@]3(CCN4CC6CC6)[C@@H](O2)C(=O)CC5)O)O
InChI	InChI	1.06	InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
InChIKey	InChI	1.06	DQCKKXVULJGBQN-XFWGSAIBSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB00704
Name	Naltrexone
Groups	approved investigational vet_approved
Description	Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Synonyms	N-Cyclopropylmethylnoroxymorphone 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one Naltrexone Naltrexona Naltrexone hydrochloride Naltrexonum Naltrexon 17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one N-Cyclopropylmethyl-14-hydroxydihydromorphinone
Brand Names	Revia Vivitrol Naltrexone Hydrochloride and Bupropion Hydrochloride Extended-Release Contrave Rpc-naltrexone Addex-1000 Contrave Extended-Release Naltrexone Hydrochloride Troxyca ER Naltrexone Embeda Naltrexone Hcl Naltrexone Hydrochloride Tablets USP Mysimba Revia - Tab 50mg Apo-naltrexone
Indication	Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
Categories	Agents Causing Muscle Toxicity Alcohol Deterrents Alimentary Tract and Metabolism Alkaloids Analgesics Antiobesity Preparations, Excl. Diet Products Central Nervous System Agents Centrally Acting Antiobesity Products Drugs Used in Addictive Disorders Drugs Used in Alcohol Dependence Hepatotoxic Agents Heterocyclic Compounds, Fused-Ring Morphinans Natural Opium Alkaloids Nervous System Opiate Alkaloids Opiate Antagonists Opioid Antagonists Opioids Peripheral Nervous System Agents Phenanthrenes Sensory System Agents Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome UGT1A1 Substrates
ATC-Code	N02AA56 N07BB04 A08AA62
CAS number	16590-41-3

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
Mu-type opioid receptor	MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRT...	unknown	antagonist
Kappa-type opioid receptor	MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLE...	unknown	antagonist
Delta-type opioid receptor	MEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAI...	unknown	antagonist
Sigma non-opioid intracellular receptor 1	MQWAVGRRWAWAALLLAVAAVLTQVVWLWLGTQSFVFQREEIAQLARQYA...	unknown	antagonist
UDP-glucuronosyltransferase 1A1	MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682